IP Library Granted Patent US 8,927,510
Granted Patent B2
US 8,927,510 · App. 12/992,797 · Granted Jan 6, 2015

Compositions and methods for inhibition of retroviruses

Inventors: Nan Yan (Boston, MA); Alan Engelman (Brookline, MA); Judy Lieberman (Brookline, MA)
Assignees: Children's Medical Center Corporation; Dana-Farber Cancer Institute, Inc.
A61K31/00C12N2740/16011A81K31/7105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,510
App. No.
12/992,797
Granted
Jan 6, 2015
Kind
B2
Abstract

Described herein are methods and compositions for the inhibition of retroviral integration and replication. The methods and compositions inhibit the activity of one or more components of the SET complex or base excision repair enzymes and induce autointegration of retroviral double-stranded nucleic acid.

Claims (5)

1. A method of decreasing retroviral nucleic acid integration into a host cell genome, said method comprising contacting a cell infected with a retrovirus with an inhibitor of one or more components of the SET complex, wherein said inhibitor decreases retroviral nucleic acid integration and wherein said inhibitor is a nucleic acid inhibitor comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

2. The method of claim 1 , wherein the inhibitor of one or more components of the SET complex increases autointegration of a retroviral nucleic acid.

3. The method of claim 1 , wherein the retrovirus is a human immunodeficiency virus (HIV).

4. A method for the treatment of a retroviral infection in a subject in need thereof, the method comprising administering to a subject in need an effective amount of a composition comprising an inhibitor of one or more components of the SET complex, wherein said inhibitor decreases retroviral infection in said subject, and wherein said inhibitor is a nucleic acid inhibitor that comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

5. The method of claim 4 , wherein the retroviral infection is a human immunodeficiency virus (HIV) infection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2014
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 034222/0110 →
MERGER Recorded Sep 9, 2014
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 033694/0934 →
Continuity (2)
Provisional Application 61053769 · May 16, 2008
Related Publication 20110142854A1 · Jun 16, 2011